Jenburkt Pharmaceuticals Ltd
Jenburkt Pharmaceuticals Ltd Company History
Jenburkt Pharmaceuticals is in the business of manufacturing, producing, developing and marketing a wide range of branded Pharmaceuticals and health care products.
2003
company's modern formulation plant at Sihor, Gujarat,has received WHO-GMP ertificationas ,as laid down by world health organization, Geneva.
2003
2004
Jenburkt Pharmaceuticals Ltd has been Declares Dividend at Rs 0.70 per equity share each of Rs 10 has been declared.
2004
2005
Jenburkt Pharmaceuticals Ltd has recommended a dividend @ 10% on Equity Shares of the Company.
2005
2006
Jenburkt Pharmaceuticals Ltd has recommended a dividend @ 12.5% on Rs 10/- paid up Equity Shares of the Company.
2006
2007
Jenburkt Pharmaceuticals Ltd has recommended a dividend of 12.5% per equity share of Rs 10/- each.
The Company is in receipt of a prestigious credit rating Certification from NSIC-CRISIL. The Company has been awarded with the highest possible rating as "CRISIL SE 1A", under the captioned category. The rating indicates "Highest performance capability and High financial strength".
E-mail ID for Investor Complaints:
[email protected]
2007
2008
The Company has recommended a dividend of 12.5% equity share of Rs 10/-.
2008
2009
Jenburkt Pharmaceuticals Ltd has recommended a dividend of Rs 1.80 (18%) per equity share of Rs 10/- each.
2009
2010
Jenburkt Pharmaceuticals Ltd has recommended a dividend of Rs. 3.00 (30%) per equity shares of Rs. 10/- each.
The Company was bestowed with "National Award for Excellence in Cost Management-2009" as the "FIRST" awardees under the category of the "Private Manufacturing-(small)" by the Institute of Cost and Works Accountants of India (ICWAI), at New Delhi.
2010
2011
The Company has recommended a Dividend of Rs. 3.50 (35%) per equity share of Rs. 10/- each.
The Company was bestowed with "National Award for Excellence in Cost Management-2010" as the "FIRST" awardee under the category of the "Private Manufacturing-(small)" by the Institute of Cost and Works Accountants of India (ICWAI).
The Company has been awarded an NSIC-CRISIL rating of "NSIC-CRISIL SE-1A" on June 30, 2011. The rating indicates "Highest performance capability and High financial strength".
2011
2012
Jenburkt Pharmaceuticals Ltd has recommended a dividend of Rs. 3.50 (35%) per equity share of Rs. 10/- each.
2012
2013
Shri. Ashish U. Bhuta has been appointed as the Chairman and Managing Director of the Company
2013
2014
The Company has recommended a Dividend of Rs. 5.10 (51%) per equity share of Rs. 10/- each.
Ms. Devangi Sanjeev Shah has been appointed of Woman Director
2014
2020
Jenburkt, launched Favipiravir (Favivent) to fight COVID-19
2020
